LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Tests Available for Cervical and Other Genital HPV Cancers

By LabMedica International staff writers
Posted on 23 Mar 2015
Print article
A molecular laboratory service now offers new human papillomavirus (HPV) testing of low- and high-risk genotypes using cutting-edge technology, including next- generation DNA sequencing (NGS) platforms.

Genital human papillomaviruses (HPV) are a group of more than 40 related viruses. 14 high-risk genotypes are associated with most cases of cervical cancer and anal cancers; many vaginal, vulvar, and penile cancers; and some oropharyngeal cancers. Two genotypes, HPV 16 and HPV 18, are responsible for about 70% of all cervical cancers. HPV testing is recommended as part of routine cervical cancer screening for women 30 to 65 years of age, along with Pap smears every 5 years.

Medical Diagnostic Laboratories, LLC (MDL; Hamilton, NJ, USA), and its division the Institute for Biomarker Research, have announced now offering a diverse panel for high-accuracy genetic HPV testing. The MDL “HPV Type-Detect 3.0” tests identify the presence of DNA from: 5 low-risk HPV genotypes: HPV 6, 11, 42, 43, 44; and 14 high-risk genotypes: HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68. MDL's HPV reflex testing includes HPV 16 and HPV 18 RNA expression, HPV 16 viral load, HPV 16 integration status and E6 variants at no additional charge.

Minimally-invasive, simple specimen collection methods are provided: cervico-vaginal swabs for females utilizing the OneSwab or ThinPrep platforms, or urine for males utilizing the UroSwab platform.

MDL’s Institute for Biomarker Research division was established to create, validate, and commercialize innovative diagnostic assays for clinical practice. MDL, a member of the Genesis Biotechnology Group (Hamilton, NJ, USA), is a CLIA-certified, CAP-accredited laboratory specializing in high complexity, state-of-the-art, automated DNA-based molecular analyses.

Related Links:

Medical Diagnostic Laboratories


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more